Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit.
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials WILMINGTON, ...
Phase 3 studies report meaningful reductions in exacerbations across broad patient groups Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive ...
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of ...
Positive high-level results from the phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualised rate of ...
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically ...
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically ...
Before the pandemic, roughly half of counties had kindergarten vaccination rates high enough to prevent measles outbreaks. After the pandemic, many counties increased their vaccination rates, reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results